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ABSTRACT
Introduction: Many maternity providers
recommend that women with diabetes in pregnancy
express and store breast milk in late pregnancy so
breast milk is available after birth, given (1) infants of
these women are at increased risk of hypoglycaemia in
the first 24 h of life; and (2) the delay in lactogenesis II
compared with women without diabetes that increases
their infant’s risk of receiving infant formula.
The Diabetes and Antenatal Milk Expressing (DAME)
trial will establish whether advising women with
diabetes in pregnancy (pre-existing or gestational) to
express breast milk from 36 weeks gestation
increases the proportion of infants who require
admission to special or neonatal intensive care units
(SCN/NICU) compared with infants of women receiving
standard care. Secondary outcomes include birth
gestation, breastfeeding outcomes and economic
impact.
Methods and analysis: Women will be recruited
from 34 weeks gestation to a multicentre, two arm,
unblinded randomised controlled trial. The intervention
starts at 36 weeks. Randomisation will be stratified by
site, parity and diabetes type. Women allocated to the
intervention will be taught expressing and encouraged
to hand express twice daily for 10 min and keep an
expressing diary. The sample size of 658 (329 per
group) will detect a 10% difference in proportion of
babies admitted to SCN/NICU (85% power, α 0.05).
Data are collected at recruitment (structured
questionnaire), after birth (abstracted from medical
record blinded to group), and 2 and 12 weeks
postpartum (telephone interview). Data analysis: the
intervention group will be compared with the standard
care group by intention to treat analysis, and the
primary outcome compared using χ2 and ORs.
Ethics and dissemination: Research ethics
approval will be obtained from participating sites.
Results will be published in peer-reviewed journals and
presented to clinicians, policymakers and study
participants.
Trial registration number: Australian Controlled
Trials Register ACTRN12611000217909.
BACKGROUND
Diabetes is the second highest contributor to
loss of health in Australia.1 Type 2 diabetes
and gestational diabetes (GDM) are increas-
ing globally.2 GDM occurs on average in 7%
of pregnancies (range 1–14% depending on
the population characteristics and diagnostic
tests used),2 and is the strongest single popu-
lation predictor of type 2 diabetes.3 An add-
itional 1% of females aged below 44 years
have pre-existing diabetes (type 1 or 2),4 with
type 2 diabetes increasing in women of child-
bearing age.5 Since 2009, women found to
have glucose intolerance at the ﬁrst preg-
nancy visit are diagnosed as having type 2
diabetes (not GDM).2 In Victoria in 2008,
6.1% of all women giving birth had diabetes
in pregnancy (personal communication, A
Cooper, Perinatal Data Collection Unit). At
the planned original study sites, the Royal
Women’s Hospital (RWH) and Mercy
Hospital for Women (MHW), 7.7% (495/
6443) and 10.3% (690/5748) of women,
respectively, giving birth in 2009 had diabetes
in pregnancy.
Pregnancies affected by diabetes have
increased risk of perinatal complications,
Strengths and limitations of this study
▪ This will be the first study to provide rigorous
evidence regarding the practice of antenatal
expression of colostrum in late pregnancy for
women with diabetes in pregnancy.
▪ It will explore the safety and efficacy for mother,
fetus and infant.
▪ The conclusions about antenatal expressing will
be restricted to women with diabetes in preg-
nancy, but if this practice is found to be safe and
effective for this high-risk group, the conclusions
are likely to be applicable to other women as well.
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including increased perinatal mortality for infants of
women with type 1 diabetes.6–8 In GDM, poorer gly-
caemic control is also associated with adverse infant
outcomes.9
Infants of women with diabetes in pregnancy are at
increased risk of hypoglycaemia (secondary to hyperinsu-
linism) and other morbidities in the early neonatal
period (eg, macrosomia, respiratory distress syndrome,
prematurity, congenital anomalies, polycythaemia, jaun-
dice).5 10 They are more likely to themselves develop dia-
betes, and have an increased risk of obesity later in life.5
A strategy to decrease the risk of these infants develop-
ing diabetes or impaired glucose tolerance later in life
would be one way of interrupting the cycle of diabetes.
One such strategy is to increase the rate of exclusive
breastfeeding from birth in these infants, given that early
exposure to cow’s milk protein increases the incidence of
both type 1 ( juvenile onset) and later onset type 2 dia-
betes.11–13 However, infants of women with diabetes are
at high risk of not being exclusively breastfed for a
number of reasons. Studies have found generally that
women with diabetes are less likely to breastfeed than
other women, and likely to breastfeed for a shorter dur-
ation,14–17 although one study has found that where
breastfeeding is encouraged and supported, women with
diabetes can be just as successful as women without
diabetes.18
Lactogenesis II, the onset of copious milk production,
usually occurs 30–40 h after birth.19 Women with diabetes
experience up to a 24 h delay in lactogenesis II compared
with women without diabetes,20–24 as do women with
glucose intolerance, increasing their infants’ risk of
receiving infant formula.25 Women with diabetes are also
at risk of other comorbidities, most commonly
obesity.26 27 In turn, obese women28 and obese women
with diabetes29 are less likely to successfully breastfeed.
Separation of mother and infant following caesarean
birth (also more likely in women with diabetes in preg-
nancy27 30) and/or admission to special and neonatal
intensive care units (SCN/NICU) further decreases the
likelihood of establishing breastfeeding.31 32
Since infants of women with diabetes are at increased
risk of hypoglycaemia,10 they require blood glucose
monitoring and are often admitted to the SCN. If
infants are hypoglycaemic and their mother is unable to
provide a sufﬁcient volume of expressed breast milk in
addition to breastfeeding, they may receive supplemen-
tation with infant formula or intravenous glucose. This
has led to a practice whereby some women with diabetes
in pregnancy are being advised to express breast milk
before their infant’s birth.
Current practice
Increasing numbers of maternity providers are encour-
aging pregnant women with diabetes to express and
store breast milk (colostrum) in the last weeks before
their expected delivery date,33–38 so that breast milk is
available in the postpartum period, thereby possibly
avoiding infant formula if neonatal hypoglycaemia
needs management with supplementary formula
feeding. Some organisations have implemented guide-
lines for antenatal expressing of colostrum,39 40 and in a
recent book for consumers, there is a section entitled
“Getting a head start: expressing milk before your baby
is born” (ref.41, p.57). This practice presupposes that
establishing a supply of colostrum prebirth might ameli-
orate: (1) the number of infants of women with diabetes
who receive infant formula or intravenous glucose if sup-
plementary feeding is required to treat neonatal hypo-
glycaemia (stored colostrum could be used); (2) the
delay in lactogenesis II in women with diabetes and (3)
the number of infants of women with diabetes admitted
to the SCN. These recommendations for practice have
not been investigated and are therefore theoretical, and
there is very limited evidence regarding the safety or efﬁ-
cacy of encouraging antenatal expressing of breast milk.
The evidence
A retrospective cohort study from the UK included 94
women, and found that infants of women with diabetes
who expressed were born 1 week earlier on average
(37.1 weeks (SD 2.6), compared with 38.2 weeks (SD
2.2), p=0.06), and were more likely to be admitted to
the SCN.42 We conducted a pilot study in 2007 that also
provided some evidence, and provided the baseline data
to undertake the proposed randomised controlled trial
(RCT).43 We recruited 43 women with diabetes in preg-
nancy who agreed to undertake antenatal expressing
(35% of those eligible agreed to participate when
invited) and we conducted a concurrent audit of clinical
outcomes in a group of infants of similar women (with
diabetes in pregnancy) to provide ‘control’ data. Women
in the expressing pilot completed a demographic ques-
tionnaire, were then taught how to express colostrum
and encouraged to do so for 10 min twice daily from
36 weeks gestation. They were advised on the safe
storage of colostrum, which they froze for their baby’s
use after birth. Women kept a diary documenting their
expressing and completed telephone interviews at 6 and
12 weeks postpartum. We found that 30% of infants in
the pilot were admitted to SCN compared with 17% of
‘control’ infants, and that reasons for admission to SCN
were similar in the two groups.43 Intravenous glucose
use was 14% for pilot infants and 8% for control infants
(RR=1.77; 95% CI 0.63 to 4.96). There was no evidence
of any fetal compromise based on cardiotocographs
(CTGs) undertaken after the ﬁrst expressing episode.
Women recorded blood sugar levels (BSLs) following
their ﬁrst three expressing episodes. Although the
median BSLs were normal and suggested no evidence of
hypoglycaemia at a group level, 10% (2/20) of women
had a BSL <3.5 mmol/L after the ﬁrst expressing
episode, and seven women (27%; 7/29) reported they
experienced tightenings or Braxton Hicks contractions
as a result of antenatal expressing, and one ceased the
intervention for this reason.
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The amount of colostrum women obtained varied
according to number of expressions, length of time
between onset of expressing and birth and the time
spent expressing, with a median of 14 days expressing
and 40 mL (range 5–310 mL) obtained. Although some
women found expressing difﬁcult (31%), the interven-
tion was positively received overall, and 95% (38/40) of
women would express antenatally again if the practice
was proven beneﬁcial. More infants in the pilot received
exclusive breast milk during their postpartum hospital
stay (37%) compared with the ‘control’ group (27%;
RR=1.38; 95% CI 0.82 to 2.31).
In January 2010, we conducted a telephone survey of
48 tertiary and large metropolitan and regional mater-
nity hospitals across Australia providing care for 109 465
births per year and found that 30 of these services
(63%; 65 478 births) recommend antenatal milk expres-
sing.44 Of these, 21 (70%) recommended antenatal
expressing primarily to women with diabetes in preg-
nancy (although the practice is also being recom-
mended to women with other high-risk pregnancies),
and 11 (37%) had a policy or guideline for antenatal
milk expressing. Across the 11 services with a policy or
guideline for antenatal milk expressing, the mean gesta-
tion recommended for start of expressing was 36 weeks
(range 30–37 weeks). Of the 18 services (38%; 43 987
births) who did not recommend this practice, 5 (28%)
discontinued antenatal expressing based on the recom-
mendations of our pilot observational study,43 and await
evidence to inform this practice.44
A recent Cochrane review identiﬁed no RCTs that
investigated the practice of expressing and storing breast
milk during pregnancy, and concluded that there is no
high-level systematic evidence to inform the safety and
efﬁcacy of this practice.38 Rigorous evidence is urgently
required to inform the clinical practice of antenatal
expression of colostrum.44 This paper describes the
protocol for an adequately powered RCT exploring the
practice of advising women with diabetes in pregnancy
to express breast milk from 36 weeks gestation.
METHODS
A multicentre, two arm, unblinded RCT design will be
used to compare the practice of antenatal milk expres-
sing with standard care, for women with pre-existing or
GDM. In the original trial design we included only
women with diabetes in pregnancy who required insulin,
choosing this group because they are the women for
whom antenatal expressing is most often suggested, yet
are at the highest risk of perinatal complications, particu-
larly if glycaemic control is poor. This inclusion criterion
changed, as detailed below in the sample size section.
Aims
Primary aim
To establish whether the practice of antenatal expressing
of colostrum from 36 weeks gestation, for women with
diabetes in pregnancy, increases the proportion of
infants who require admission to the SCN or NICU com-
pared with the infants of similar women receiving stand-
ard care.
Primary hypothesis
Infants of women with diabetes in pregnancy who start
antenatal expressing of colostrum from 36 weeks gesta-
tion will be more likely to be admitted to the SCN or
NICU during the primary hospitalisation after birth
compared with the infants of women with diabetes in
pregnancy receiving standard care.
Secondary aims
To determine whether antenatal expressing of colostrum
from 36 weeks gestation for women with diabetes in
pregnancy, compared with similar women receiving
standard care:
A. Increases the proportion of infants receiving exclusive
breast milk at 3 months of age (ie, is effective in pro-
moting exclusive breastfeeding);
B. Decreases the mean gestation at birth (ie, is harmful);
C. Increases the proportion of infants receiving exclusive
breast milk during initial hospital stay (ie, is
effective).
We will also:
D. Test the cost and cost-effectiveness of this interven-
tion compared with standard care;
E. Explore the views and experiences of women partici-
pating in this trial;
F. Collect data on other outcomes—for example, fetal
well-being associated with expressing; volumes of
antenatal colostrum obtained; time to onset of lacto-
genesis II (onset of copious milk production).
Table 1 summarises the potential harms and beneﬁts
of antenatal expressing of colostrum.
Table 1 Potential harms and benefits of antenatal breast
milk expressing
Potential harms Potential benefits
Increased admissions to
SCN/NICU (shows
increased neonatal
morbidity and
mother-infant separation)
Increased exclusive
breastfeeding during initial
hospital stay
Increased exclusive
breastfeeding at 3 months
postpartum
Increased duration of any
breastfeeding
Decreased mean duration
of pregnancy
Improved maternal
satisfaction
Increased requirement for
intravenous glucose
Decreased risk of
subsequent diabetes for the
infant
SCN/NICU, special or neonatal intensive care units.
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Study sample
All eligible women booking for maternity care at the
trial sites during the recruitment period will be offered
study participation.
Inclusion criteria: Any woman
1. With pre-existing or GDM;
2. Between 34 and 36 weeks gestation (but not more
than 37 weeks);
3. With a singleton pregnancy in a cephalic presentation;
4. Attending the study sites for pregnancy care as a
public patient;
5. Planning to breastfeed and
6. Able to speak and read in English.
Exclusion criteria: Women with
1. Any history of antepartum haemorrhage, or placenta
praevia (even in the absence of any antenatal
bleeding);
2. An unknown or classical caesarean section scar or
more than one lower segment caesarean section scar;
3. Any suspicion of fetal compromise including known
or suspected intrauterine growth restriction, docu-
mented macrosomia (estimated fetal weight ≥95th
centile) with abdominal circumference >97th centile,
polyhydramnios or any abnormal tests of fetal well-
being (whether clinically, ultrasound or CTG based);
4. A known fetal anomaly;
5. Hypertension and proteinuria—if any concerns
about fetal well-being;
6. A serious maternal mental health issue, other severe
maternal obstetric/medical issue.
In some sites there are small proportions of infants
who are automatically admitted to the SCN after birth,
for example, infants of women who have type 1 or 2 dia-
betes, or women on higher doses of insulin. In these
sites, given the primary outcome is SCN/NICU admis-
sion, the women in those groups will be ineligible for
inclusion in the trial.
Recruitment
Eligible women will be identiﬁed and offered participa-
tion by a study midwife at 34–36 weeks gestation, to
maximise the opportunity to recruit women. If the
woman is interested she will provide written consent and
complete a questionnaire regarding demographic details
and breastfeeding intentions. Randomisation occurs at
36 weeks gestation, so recruitment and randomisation
will often be a two-stage process. Prior to randomisation
women will have a preliminary 20 min CTG, and if the
CTG is assessed as reactive and without signiﬁcant
uterine activity, the woman will be randomised to one of
the two trial arms. Women allocated to the intervention
will be taught hand expressing at that time (detailed
more fully below), with a CTG during this ﬁrst 10 min
expressing episode and for 20 min after. The schedule
of participant enrolment, intervention and assessments
is shown in ﬁgure 1.
Randomisation procedure
Randomisation is stratiﬁed by site, ﬁrst baby or not, and
diabetes type (ie, pre-existing (type 1 or 2), gestational
requiring insulin or gestational not requiring insulin). A
computerised random number generator was used to
select random permuted blocks with at least three differ-
ent block sizes. A system designed and administered by
the Clinical Epidemiology and Biostatistics Unit at
Murdoch Childrens Research Institute is accessed by the
internet to ascertain women’s allocation.
The intervention
Women randomised to the intervention will receive all
standard advice and care (guided by existing hospital pro-
tocols) as well as receiving instructions on the interven-
tion. They will be taught how to hand express colostrum
(see online supplementary ﬁle 1). Women will be
encouraged to express twice daily for no more than
10 min until being admitted to hospital to give birth,
unless any concerns arise which indicate that the inter-
vention should cease (see below).
Women will be provided with written and verbal
instructions on the safe storage and transportation of
colostrum (see online supplementary ﬁle 1). Expressed
colostrum will be labelled with the woman’s hospital
medical record number and kept in syringes in her
home freezer. Women will be asked to bring the frozen
colostrum in an ‘esky’ (cold storage box) when they are
admitted for the birth. Women will be provided with all
the equipment they require for this intervention: syr-
inges (2 and 5 mL), small eskies, ice pack and specimen
bags, labels with medical record number and diaries to
document each episode of expressing.
A dedicated freezer will be available at each trial site
for storage of antenatally expressed frozen colostrum.
Midwifery and neonatal staff will receive education
about the trial and be informed as to where to store the
frozen expressed breast milk.
Ensuring maternal and fetal well-being
Surveillance in hospital
Women in the intervention group will undertake an
expressing episode under CTG surveillance at the time
they are taught expressing (immediately after randomisa-
tion). If a woman requires further CTGs during their
pregnancy care she will be asked to do one of her
expressing episodes during those CTGs, as the uterus
may become more sensitive to the resultant oxytocin
surge with advancing gestation. The protocol for subse-
quent CTGs and expressing will be identical to that of
the initial expressing episode, that is, preliminary CTG,
express for 10 min, then continue the CTG for 20 min
postexpression. The CTG must be reactive prior to start-
ing expressing. Immediate discontinuation of expressing
will occur if there are any signs of fetal compromise
(fetal tachycardia, reduced variability, late decelera-
tions), or if there is excessive uterine activity (either a
hypertonic contraction (one lasting longer than 90 s), or
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tachysystole (>5 contractions per 10 min period)). Each
participating centre will follow their existing protocol for
management of fetal distress, including availability of
acute tocolysis and on-site obstetric support.
Surveillance at home
Women will be advised of precautions related to expres-
sing in the antenatal period and informed that if they
have concerns regarding any of these issues they should
telephone the study midwife, or the emergency depart-
ment/birth suite of their relevant hospital after hours.
Instructions will be given regarding the importance of:
1. Noting normal fetal activity prior to expressing.
2. Reporting any complications after expressing, such as
excessive uterine activity, vaginal blood loss, decreased
fetal movements or signs of hypoglycaemia.
3. Measuring BSLs after the ﬁrst three episodes of
expressing, to ensure that the expressing is not
causing hypoglycaemia (which can occur with breast-
feeding).45 A consultant endocrinologist will advise
the research team on maternal diabetes care as
needed, and assist with interpretation of relevant
outcomes.
Standard care
All women with pre-existing or GDM are seen by a dia-
betes educator for management of their diabetes.
Additionally, all women discuss breastfeeding with mid-
wives during pregnancy, and at all sites women can ask
to see a lactation consultant in the antenatal period if
they wish. No site can participate in the trial if they rec-
ommend that women express colostrum in the antenatal
period.
Management of neonatal hypoglycaemia
The intervention being tested is not aimed at preventing
hypoglycaemia; however, in practice the aim of many
clinicians who advise antenatal milk expressing for this
group is to avoid the use of formula for supplementary
feeding if/when neonatal hypoglycaemia occurs. Based
on our pilot data, approximately half of the admissions
to SCN or NICU will be for neonatal hypoglycaemia.43
We will measure the incidence and duration of neonatal
hypoglycaemia; however, it is not expected that encour-
aging women to express prior to birth could of itself
prevent neonatal hypoglycaemia.
Figure 1 Schedule of
enrolment, intervention and
assessments for the DAME
(Diabetes and Antenatal
Expressing) trial.
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Existing guidelines for management of newborn
infants at risk of hypoglycaemia, including infants of
women with diabetes in pregnancy, will be followed.
While there may be slight variations in guidelines by trial
site, for the purposes of data analysis neonatal hypogly-
caemia is deﬁned as a true blood glucose (TBG)
<2.6 mmol/L as measured on a blood gas analyser (or
portable point of care TBG analyser) or in the laboratory.
Sites whose guidelines for management of newborn
infants at risk of hypoglycaemia are too different from
this are not eligible to participate in the trial, and site
guidelines are reviewed by the trial neonatologist prior to
a decision about any site’s suitability for inclusion.
Although bedside testing with a glucometer is possible
(providing BSLs), this method is not accurate at low
blood glucose levels, when a TBG is mandatory. Prompt,
standardised and accurate blood glucose measurement
of TBG is optimal,46 47 and in the trial will eliminate
measurement bias in either trial arm. A portable point of
care TBG analyser will facilitate prompt, accurate TBG
measurement at the bedside without separation of
mother and baby—crucial in supporting early
breastfeeding.
Stratiﬁcation by site ensures that any slight variation in
infant glucose management will not affect trial out-
comes. Regardless of group assignment, mothers will
breastfeed their infants, and express their milk post-
partum if required. The ﬁrst response to hypoglycaemia
(as per existing clinical guidelines at the two primary
trial sites, RWH and MHW) is a prescribed volume (30–
60 mL/kg/day of supplemental feed of expressed breast
milk or infant formula, or glucose gel (0.5 mL/kg of
40%)) massaged into buccal mucosa. Hypoglycaemia
unresponsive to supplemental feeding triggers admission
to SCN/NICU, more frequent, larger supplemental
feeds, further glucose gel or intravenous glucose
therapy, to achieve normal TBGs.
Process evaluation
Adherence to the study protocol and intervention ﬁdel-
ity will be monitored.
1. Measures of intervention exposure: Women in the inter-
vention group will keep a diary of antenatal expres-
sing, noting: date and time of day each expressing
episode takes place, length of each expressing
episode and volume of colostrum expressed. Women
in the control group will be asked at the 1–2 week
interview if they expressed antenatally, to check for
any cross-over.
2. Monthly meetings with all project staff will include
discussion of protocol adherence, measurement and
documentation.
3. Intervention evaluation by participants: The tele-
phone interview at 12 weeks postpartum will include
questions regarding women’s views and experiences
of being in the trial.
Sample size
Given the aim of antenatal expressing of breast milk is
to beneﬁt infants of women with diabetes in pregnancy,
we debated whether our primary outcome should test
efﬁcacy or safety. Because our pilot data suggested
potential harm, we chose the primary hypothesis to test
safety. We are also powered to test the listed secondary
outcomes.
Primary outcome
As aforementioned, when we designed the trial origin-
ally, we included only women with diabetes in pregnancy
who required insulin, and our sample size calculations
were based on estimates of this group. With that popula-
tion we needed an estimated sample size of 658 women
(329 in each group) based on 80% power (α 0.05), and
allowing 5% loss to follow-up. This allowed the detection
of an increase in the proportion of infants of women
(requiring insulin in pregnancy) who are admitted to
SCN or NICU in the primary hospital admission follow-
ing birth, from 20% in the control group to 30% in the
intervention group. This estimate was derived from the
pilot and audit data presented above.
Secondary outcomes
This sample size also allows detection of:
A. A difference in exclusive breastfeeding at 3 months
of 12% (40% in the control group compared with
52% in the intervention group; assuming the infants
in the intervention achieve the same rate as the state-
wide data and as per our pilot, ie, 52%; requires
n=254);
B. A difference in the mean duration of pregnancy
(38 weeks in the control group compared with
37 weeks in the intervention group; requires n=184;
means, SDs derived from Soltani study42) and
C. A difference in exclusive breastfeeding during initial
hospital stay of 12% (25% in the control group com-
pared with 37% in the intervention group).
Sample size revision May 2012
Recruitment to the trial as per the original criteria
started in July 2011. In May 2012, it was agreed to
amend our inclusion criteria to include all women with
diabetes in pregnancy. This was due to two factors (A)
the slow recruitment rate due to smaller numbers of eli-
gible women than anticipated, and (B) expert advice
from outside the research group recommending that
the external validity of the trial would be increased if
the criteria were broadened to also include women with
diabetes in pregnancy who did not require insulin.
The change of inclusion criteria meant that a baseline
rate of admission to the SCN or NICU would be 17%
rather than 20% as per our original sample size calcula-
tions (based on a review of all 2011 outcome data for
women with diabetes in pregnancy at the RWH). We
undertook various recalculations to address this.
Regarding the sample size with the altered baseline:
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▸ To detect 10% absolute difference (as in the original
calculation) we would need 289 per group—this
would be a decrease in sample size—which none of
the team considered optimal;
▸ To detect a 50% relative increase to 25.7% would
need 379 per group, that is, 758 (100 more than
current sample of 658)—again this is not ideal as the
study is not funded for this and we did not use this
difference in our original calculations;
▸ Or we could maintain current sample size (658) and
describe the study power to detect a 10% absolute
difference.
The ﬁnal option was chosen, that is, we agreed to
maintain the current sample size and assume increased
power to detect 10% absolute difference. Allowing for
5% loss to follow-up, the original sample size of 658
would provide 625 women at primary outcome measure-
ment. This would detect a change in primary outcome
from 17% to 27% with a power of 85%. All the original
secondary outcome comparisons described above will be
maintained given the sample size has not altered.
Outcome variables
Primary outcome
Proportion of infants admitted to SCN or NICU.
Secondary outcomes
A. Proportion of infants receiving exclusive breast milk
at 3 months of age;
B. Gestational age at birth;
C. Proportion of infants receiving exclusive breast milk
during initial hospital stay;
D. Cost of the intervention to hospitals and to women
and cost-effectiveness against breastfeeding outcomes;
E. Women’s views and experiences;
F. Fetal well-being associated with expressing (assessed
by CTG at initial then subsequent opportunistic CTG
episodes); antenatal expression episodes, timing and
volumes collected (intervention group only); time to
lactogenesis II.
Potential explanatory variables
G. Reasons for SCN/NICU admissions;
H. Hypoglycaemia treatments in maternity or SCN/
NICU including glucose gel, intravenous glucose,
glucagon, hydrocortisone;
I. Length of time until three consecutive infant TBG
levels ≥2.6 mmol/L;
J. Maternal blood glucose levels following ﬁrst three
expressing episodes;
K. Maternal morbidity that could be related to expres-
sing, for example, premature labour.
Data collection
Maternal and infant
Demographic data (including age, education, marital
status, ethnic background, smoking) will be collected by
questionnaire at recruitment, prior to randomisation.
Obstetric/neonatal medical outcomes will be abstracted
from the medical record following the birth by research-
ers blinded to group allocation.
Other outcome data will be collected by telephone admi-
nistered questionnaire at 1–2 and 12 weeks postpartum.
Women in the intervention arm will complete a diary of
their expressing activity.
Economic evaluation
Resource use data will be collected from the medical record
following birth and from women’s self-reported use of
health care and other resources in the 12 weeks after the
birth. Costs included in the economic evaluation are those
relating to care provided by the hospital (including admis-
sion to SCN/NICU) and women’s (infants’) use of health-
care and other societal resources over the period of the
evaluation. Measured resource use will be valued using exist-
ing unit cost estimates (eg, Diagnosis Related Groups cost
weights for hospital admissions for mother and infant48 and
Medicare fee schedules for any attendances at the women’s
local doctor).49 As the primary outcome measure is itself a
resource use item, economic evaluation will be expressed as
cost-effectiveness analysis against exclusive breastfeeding at
3 months.
Blinding: The nature of the trial necessitates non-blinding
of participants assigned to the intervention group, so that
staff know to look for expressed breast milk in the freezer if
it is available and required, and at most sites both the inter-
vention and control groups need to be non-blinded to
ensure that point of care TBGs are performed rather than
BSLs, as most sites do BSLs unless indicated (rather than the
TBGs required by this trial). Staff at sites that routinely
undertake TBGs for all infants of women with diabetes in
pregnancy will be blinded to women in the control group.
Abstraction of medical record data will be undertaken
blinded to group allocation; data will be presented to the
data monitoring committee for the interim analysis in
unlabelled study groups; and the research team will remain
blinded to group allocation at all stages prior to ﬁnal data
analysis.
Data analysis
Data will be collected to meet the CONSORT guidelines
for reporting of randomised trials,50 including data on
eligible non-participants. The ﬁrst stage of analysis will
check the comparability of participants allocated to the
two groups. The intervention group will be compared
with the standard care group by intention to treat ana-
lysis. The primary outcome measure will be compared
using χ2 tests and ORs. Comparison of means will be
undertaken for continuous variables using t tests where
data are normally distributed or Mann-Whitney U tests
will compare medians otherwise. Ranked or Likert-type
scales will be analysed using cumulative ORs. Where
there are differences in baseline characteristics of the
women in the two groups which might be associated
with outcomes, an additional multivariate analysis will be
carried out. Duration of breastfeeding will be compared
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using Kaplan-Meier statistics. Content analysis will be
used to summarise open-ended comments.51
Data and Safety Monitoring Committees: A Data
Monitoring Committee including a statistician, a midwife
and an obstetrician (experienced in conducting RCTs)
will undertake an interim analysis after half the women
have given birth. A Safety Committee including a neonat-
ologist, a midwife and an obstetrician (all experienced
clinicians and researchers) will review reports of any
adverse events, for example, an excess of any of the pre-
deﬁned adverse events for women or infants, blinded to
group allocation (see online supplementary ﬁle 2 for list
of events). Terms of reference for each of these commit-
tees will guide frequency of reviews and the conditions
under which either committee would advise the research
team that enrolment to the trial should cease.
DISCUSSION
This will be the ﬁrst study to provide rigorous evidence
regarding the practice of antenatal expression of colos-
trum in late pregnancy for women with diabetes in preg-
nancy. It will explore the safety and efﬁcacy for mother,
fetus and infant.
There remains widespread national and international
interest in the outcomes of this trial, and the controversy
can be seen in a recent review which concluded ante-
natal expressing should be encouraged: “Although
Forster et al43 have argued the teaching of [antenatal
expressing] should cease until the practice is proven to
be safe and effective…an ethical dilemma now exists…as
to whether the beneﬁts of early colostrum feedings in
at-risk babies outweighs the unproven side effect of pre-
mature labour.52 In the absence of evidence, the clear
beneﬁts of early feedings of colostrum should outweigh
the unsupported risks of ceasing [antenatal expressing]
education.”53
TRIAL STATUS
Approval has been granted from the following Human
Research Ethics Committees (reference number in
brackets): RWH (11/07); MHW (11/06); La Trobe
University (11-004); Monash Medical Centre (12181-B);
Barwon Health (13/06); Peninsula Health (14/PH/21).
Recruitment started at RWH in June 2011, followed by
MHW in July 2011. In May 2012, due to (A) the slow
recruitment rate resulting from low numbers of eligible
women, and (B) external expert advice to include
women with diabetes in pregnancy who did not require
insulin, thereby increasing the trial’s external validity, it
was agreed to amend our inclusion criteria to include all
women with diabetes in pregnancy (not just those
requiring insulin) and to identify and recruit further
trial sites. Monash Medical Centre started in October
2012 and Barwon Health (Geelong Hospital) in April
2013. The last site, Frankston Hospital, had ethics
approval from Peninsula Health in July 2014 and recruit-
ment will start soon.
In the original protocol women who had a history of
spontaneous preterm birth or who had threatened
preterm birth in the current pregnancy were excluded,
however following the Safety Committee review of the
ﬁrst 100 births, which found no evidence of contractions
following expressing, and because no woman is rando-
mised prior to 36 weeks gestation, this exclusion criter-
ion was removed.
Monitoring CTGs
The CTGS for all of the ﬁrst 100 women who have given
birth (prerandomisation, during and postexpressing)
have been assessed by investigator SPW, with no sign of
fetal compromise or increase in contractions as a result
of expressing.
Substudies
1. Onset of lactation: In order to determine if the onset
of lactation is delayed in women with diabetes, we are
recruiting a comparison group of 200 women without
diabetes. Women are being recruited in the postnatal
wards at the RWH in 2014, and followed by tele-
phone at 1–2 weeks postpartum, using identical ques-
tions to the DAME interview.
2. Antenatal colostrum: We plan to conduct a biochemical
analysis of some excess samples of antenatal colos-
trum that infants have not required.
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